Researcher
Franki Speleman
- Disciplines:Cell signalling, Cellular interactions and extracellular matrix, Cytoskeleton, Epigenetics, Cell death, Cell division, Cell growth and development, Cell movement, Transcription and translation, Medical epigenomics, Medical metagenomics, Medical genomics, Genetics, Molecular and cell biology not elsewhere classified, Intracellular compartments and transport, Membrane structure and transport, Posttranslational modifications, Stem cell biology, Structural biology, Immunogenetics, Clinical genetics and molecular diagnostics
Affiliations
- Department of Biomolecular Medicine (Department)
Member
From1 Oct 2018 → Today - Department of Pediatrics and medical genetics (Department)
Member
From1 Jan 1993 → 30 Sep 2018
Projects
21 - 30 of 44
- Startersbeurs EVDS Lisa Depestel: The chromatin modifier PHF6 as adaptor in gene-gating coupled replicative stress in neuroblastoma and T-ALLFrom1 Dec 2017 → 30 Nov 2018Funding: Nonprofit institution or equivalents
- Novel combination therapies to combat therapy resistant neuroblastoma: translating pre-clinical investigations to clinical trialsFrom1 Oct 2016 → 31 Dec 2021Funding: Nonprofit institution or equivalents
- HBP1 as novel therapeutic target in ALK- and MYCN-driven neuroblastomaFrom1 Oct 2016 → 30 Sep 2017Funding: Nonprofit institution or equivalents
- Identification of novel therapeutic targets through multi-level (epi) genomic landscaping of replicative stress resistant neuroblastoma From1 Oct 2016 → 30 Sep 2019Funding: BOF - Other initiatives
- purchase of a technical platformFrom1 Jan 2016 → 31 Mar 2017Funding: FWO Humanitarian research project Stand up against Cancer
- Drug resistance in MYC/MYCN driven tumor entities as a consequence of replicative stress induced DNA damage response: an entry point for synthetic lethal drugsFrom1 Jan 2016 → 31 Dec 2019Funding: FWO Humanitarian research project Stand up against Cancer
- Long noncoding RNAs in cancer: deciphering the functional role of the dark matter of the human cancer genomeFrom1 Jan 2016 → 31 Dec 2022Funding: BOF - Concerted Research Project from 1994
- Research Grant Emmanuel Van de Schueren to Suzanne Vanhauwaert: BRIP1 and BIRC5 as novel therapeutic targets in neuroblastomaFrom1 Oct 2015 → 30 Sep 2016Funding: FWO Humanitarian research project Stand up against Cancer
- Epigenetic re-activation of T-ALL tumor suppressors under control of TLX1driven enhancer RNAs.From1 Oct 2015 → 30 Sep 2019Funding: BOF - Doctoral projects
- Investigation of the Polycomb-associated RNA sequence space and functional consequencesFrom1 Oct 2015 → 30 Sep 2020Funding: BOF - Other initiatives, FWO fellowships
Publications
1 - 10 of 91
- MYCN and SNRPD3 cooperate to maintain a balance of alternative splicing events that drives neuroblastoma progression(2024)
Authors: Alice Salib, Nisitha Jayatilleke, Janith A. Seneviratne, Chelsea Mayoh, Katleen De Preter, Franki Speleman, Belamy B. Cheung, Daniel R. Carter, Glenn M. Marshall
Pages: 363 - 377 - HTSplotter : an end-to-end data processing, analysis and visualisation tool for chemical and genetic in vitro perturbation screening(2024)
Authors: Carolina de Carvalho Nunes, Jasper Anckaert, Fanny De Vloed, Jolien De Wyn, Kaat Durinck, Jo Vandesompele, Franki Speleman, Vanessa Vermeirssen
- Human iPSC modeling recapitulates in vivo sympathoadrenal development and reveals an aberrant developmental subpopulation in familial neuroblastoma(2024)
Authors: Stéphane Van Haver, Yujie Fan, Sarah-Lee Bekaert, Celine Everaert, Wouter Van Loocke, Vittorio Zanzani, Joke Deschildre, Ines Fernandez Maestre, Adrianna Amaro, Vanessa Vermeirssen, et al.
- Preclinical exploration of the DNA damage response pathway using the interactive neuroblastoma cell line explorer CLEAN(2024)
Authors: Jonatan Linus Gabre, Peter Merseburger, Arne Claeys, Joachim Siaw, Sarah-Lee Bekaert, Franki Speleman, Bengt Hallberg, Ruth H Palmer, Jimmy Van den Eynden
- Exploration of neuroblastoma xenograft models for tumor extracellular RNA profiling in murine blood plasma(2023)
Authors: Jill Deleu, Hanne Van Droogenbroeck, Jasper Anckaert, Anneleen Decock, Jilke De Wilde, Kaat Durinck, Liselot Mus, Justine Nuytens, Muhammad Rishfi, Kathleen Schoofs, et al.
- Mitotic dysregulation at tumor initiation creates a therapeutic vulnerability to combination anti-mitotic and pro-apoptotic agents for MYCN-driven neuroblastoma(2023)
Authors: Lei Zhai, Anushree Balachandran, Rebecca Larkin, Janith A. Seneviratne, Sylvia A. Chung, Amit Lalwani, Shoma Tsubota, Dominik Beck, Kenji Kadomatsu, Anneleen Beckers, et al.
- Memory of stochastic single-cell apoptotic signaling promotes chemoresistance in neuroblastoma(2023)
Authors: Jordan F. Hastings, Sharissa L. Latham, Alvin Kamili, Madeleine S. Wheatley, Jeremy Z. R. Han, Marie Wong-Erasmus, Monica Phimmachanh, Max Nobis, Chiara Pantarelli, Antonia L. Cadell, et al.
- Longitudinal evaluation of serum microRNAs as biomarkers for neuroblastoma burden and therapeutic p53 reactivation(2023)
Authors: Alan Van Goethem, Jill Deleu, Nurten Yigit, Celine Everaert, Myrthala Moreno-Smith, Sanjeev A Vasudevan, Fjoralba Zeka, Eveline Barbieri, Franki Speleman, Pieter Mestdagh, et al.
- Whole transcriptome profiling of liquid biopsies from tumour xenografted mouse models enables specific monitoring of tumour-derived extracellular RNA(2022)
Authors: Vanessa Vermeirssen, Jill Deleu, Annelien Morlion, Celine Everaert, Jilke De Wilde, Jasper Anckaert, Kaat Durinck, Justine Nuytens, Muhammad Rishfi, Franki Speleman, et al.
- RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition(2022)
Authors: Carolina de Carvalho Nunes, Lisa Depestel, Liselot Mus, Kaylee M. Keller, Louis Delhaye, Amber Louwagie, Muhammad Rishfi, Alex Whale, Neesha Kara, Simon R. Andrews, et al.
Patents
1 - 1 of 1